Mitochondria are responsible for the synthesis of both iron-sulfur clusters and heme, but the potential connection between the two major iron-consuming pathways is unknown. Here, we have shown that mutants in the yeast mitochondrial iron-sulfur cluster (ISC) assembly machinery displayed reduced cytochrome levels and diminished activity of the heme-containing cytochrome c oxidase, in addition to iron-sulfur protein defects. In contrast, mutants in components of the mitochondrial ISC export machinery, which are specifically required for maturation of cytosolic iron-sulfur proteins, were not decreased in heme synthesis or cytochrome levels. Heme synthesis does not involve the function of mitochondrial ISC components, because immunological depletion of various ISC proteins from mitochondrial extracts did not affect the formation and amounts of heme. The heme synthesis defects of ISC mutants were found in vivo in isolated mitochondria and in mitochondrial detergent extracts and were confined to an inhibition of ferrochelatase, the enzyme catalyzing the insertion of iron into protoporphyrin IX. In support of these findings, immunopurification of ferrochelatase from ISC mutants restored its activity to wild-type levels. We conclude that the reversible inhibition of ferrochelatase is the molecular reason for the heme deficiency in ISC assembly mutants. This inhibitory mechanism may be used for regulation of iron distribution between the two iron-consuming processes.
reduced iron across the mitochondrial inner membrane (1, 2) . Heme synthesis is rather complex, involving several mitochondrial and cytosolic enzymes that initially convert ␦-aminolevulinate to protoporphyrin IX (for review, see Ref. 3) . The final step of the pathway is the incorporation of ferrous iron into the porphyrin ring and is catalyzed by ferrochelatase (Hem15p in yeast) that is located at the matrix side of the mitochondrial inner membrane (4, 5) .
Iron incorporation into Fe/S clusters and their insertion into apoproteins is accomplished by the Fe/S cluster (ISC) assembly machinery located in the mitochondrial matrix (for review, see Refs. 6 -9) . Fe/S cluster synthesis starts with the release of sulfur from cysteine by the cysteine desulfurase Nfs1p and the assembly of a transient Fe/S cluster on the scaffold proteins, Isu1p and Isu2p (10 -13) . A similar function may be performed by Isa1p and Isa2p as judged from biochemical investigation of their bacterial homologue, iscA (14 -16) . The initial Fe/S cluster assembly on scaffold proteins requires electrons that are delivered by the electron transfer chain consisting of the [2Fe-2S] ferredoxin Yah1p and a specific NADH-dependent ferredoxin reductase (Arh1p) (2, (17) (18) (19) . Recently, Isu1p and Nfs1p have been shown to interact with Yfh1p, the yeast frataxin homologue that is thought to serve as the iron donor for Fe/S cluster synthesis (20 -22) . Steps succeeding cluster synthesis on the Isu proteins, e.g. transfer of the Fe/S cluster from Isu proteins to mitochondrial apoproteins, require the mitochondrial chaperone system Ssq1p/Jac1p as well as Grx5p, a small glutaredoxin-like protein (19, 23, 24) .
The mitochondrial ISC assembly machinery is also involved in the maturation of Fe/S proteins outside the organelle (11) . Mitochondria were proposed to export a still unknown component to the cytosol to support the formation of extramitochondrial Fe/S proteins (6) . Central components of the export pathway are the ABC transporter Atm1p (or its human orthologue ABC7) of the mitochondrial inner membrane and the sulfhydryl oxidase Erv1p/ALR of the intermembrane space (11, 25, 26) . In addition, the tripeptide glutathione was found to be required specifically in Fe/S protein maturation in the cytosol (27) .
Apart from the impairment of Fe/S cluster biosynthesis, several other defects have been reported to be caused by mutation or depletion of Isc proteins in yeast. For example, mitochondrial iron accumulation, reduced cytochrome levels, impaired heme synthesis, increased sensitivity to oxidative stress, and loss of mitochondrial DNA have been observed in various yeast "isc" mutants (i.e. mutants in components of the ISC assembly machinery) (11, 18, 28 -35) . It is noteworthy that some of these effects are prominent phenotypic markers of two ISC assembly diseases in which complex symptoms are caused by frataxin depletion in FriedreichЈs ataxia and ABC7 mutation in X-linked sideroblastic anemia and cerebellar ataxia (XLSA/A) (25, 36 -40) . Most of these effects are thought to be secondary or late consequences of the original defect in Fe/S protein maturation. In particular, this was shown for iron accumulation in a conditional frataxin gene knock-out mouse (41) . On the other hand, the observation of reduced cytochrome levels in ⌬yfh1 mutants raises the question of whether this ISC component might also play a role in heme synthesis in yeast (35) .
We became interested in the potential connection between heme and Fe/S protein synthesis because nearly nothing is known about the mechanisms that allow a cell to direct iron into either of these two processes. A mutual cross-talk between both biochemical pathways at a posttranslational level seems reasonable because some growth conditions require a coordinated synthesis of both cofactors, whereas other situations may demand a different ratio in the synthesis of Fe/S clusters and heme. A link between heme biosynthesis and iron uptake into the cell has been reported recently (42) . Because mutants defective in ISC assembly greatly increase their cellular iron uptake, this may provide another argument for the proposed connection between heme and Fe/S metabolism. To test these ideas experimentally, we initiated a systematic study and investigated cytochrome levels and heme biosynthesis rates in a broad range of isc mutants that carry defects in certain steps of Fe/S protein biosynthesis. Our results indicate that cells disrupted in any step of mitochondrial Fe/S protein biosynthesis hamper iron incorporation into heme by reversible inhibition of ferrochelatase. This cross-talk between Fe/S protein and heme biosynthesis might be used for regulating the iron distribution between these two processes in mitochondria.
MATERIALS AND METHODS

Yeast Strains and Cell Growth-
The following yeast strains were used: W303a (Mata; ade2-1 ura3-1 trp1-1 his3- 11,15 leu2-3,111) , which served as wild-type. Published mutant strains in which the endogenous promoters of the indicated ISC genes were replaced by the galactose-inducible GAL1-10 promoter were Gal-YAH1 (18), Gal-NFS1 (11), Gal-ISU1/⌬isu2 (20) , Gal-YFH1 (43), Gal-ISA1, Gal-JAC1, and Gal-SSQ1 (19) . We referred to these strains as "isc" mutants. Further, we used Gal-ATM1 (11), ⌬gsh1 (27) , and erv1 ts (26) cells. All cells were cultivated on galactose-containing rich medium agar plates (44) . To deplete cells of an Isc protein, the respective strain (precultured on glucose-containing rich medium, when necessary) was grown overnight in minimal or rich medium containing 2% glucose followed by 16 h of growth in minimal medium lacking iron chloride (for 55 Fe labeling) or in lactate medium (for preparation of mitochondria). Depletion was routinely verified by immunostaining analysis. Details of the depletion procedure for each Isc protein are given in the publications describing the respective mutant cells (see above).
Preparation of Intact Mitochondria and Mitochondrial Detergent Extracts-Mitochondria were prepared as described (45) from cultures grown overnight in lactate medium containing 0.1% glucose. Lysis of isolated mitochondria was performed at a protein concentration of 2 mg/ml in buffer D (1% dodecylmaltoside in 20 mM Hepes/KOH, pH 7.4, 150 mM NaCl, 10% glycerol) for 30 min at 4°C. Aggregates were removed by centrifugation (10,000 rpm, 10 min, 4°C).
Determination of Heme Synthesis in Organello and in Vitro-50 g of intact mitochondria, 25 l of detergent extract corresponding to 50 g of mitochondrial protein or immunopurified ferrochelatase derived from 50 g of mitochondria (see below) were used per assay. All samples were analyzed in a 500-l standard heme synthesis assay as described (1) before using buffer A (20 mM Hepes/KOH, pH 7.4, 50 mM NaCl, 0.5 mM NADH, and 0.2 M deuteroporphyrin). Samples containing intact organelles were supplemented with 0.6 M sorbitol. Heme synthesis reactions were started by adding 5 l of 100 mM ascorbate and 0.1 Ci of 55 FeCl 3 . After 5 min at 25°C, reactions were stopped with 25 l of 10 mM FeCl 3 in 5 M HCl and extracted with 500 l of butyl acetate. 200 l of the organic phase were used for scintillation counting. Zinc chelatase activity was measured in mitochondrial detergent extracts by a fluorescence assay kindly provided by R. Labbe-Bois (35, 46) .
Immunopurification of Ferrochelatase from Mitochondrial ExtractsAntibodies raised against Hem15p were coupled to protein A-Sepharose beads as described (47) . 100 l of mitochondrial extract were incubated for 30 min with 50 l of a 50% suspension of protein A-Sepharose coupled to antisera raised against ferrochelatase (Hem15p). Immunobeads were collected by centrifugation, washed three times with buffer B (20 mM Hepes/ KOH, pH 7.5, 150 mM NaCl), and eluted with sample buffer (for SDS-PAGE) or resuspended in 100 l of buffer D for measuring ferrochelatase activity. 25 l of this suspension corresponding to 50 g of intact mitochondria as starting material were used to measure ferrochelatase activity. Aliquots of the supernatants and immunobeads were analyzed for depletion of ferrochelatase by SDS-PAGE and immunostaining.
Biochemical depletion of Isc proteins was carried out by incubating wild-type mitochondrial extracts for 1 h at 4°C charged with preimmune serum or with specific antibodies raised against Nfs1p, Isu1p, Yah1p, or Yfh1p. Beads were collected by centrifugation. Aliquots of the supernatants were analyzed for depletion of Isc proteins by immunostaining and for remaining ferrochelatase activity.
Crude Fractionation of Mitochondrial Extracts-Mitochondrial detergent extracts prepared from wild-type or isc mutant cells were depleted for endogenous ferrochelatase protein as described above. Supernatants were fractionated by passing through a size-exclusion membrane (Microcon® 3 and 10; Millipore) by centrifugation for 20 -60 min according to the manufacturer's manual.
Miscellaneous Methods-The following published methods were used: manipulation of DNA and PCR (48) , transformation of yeast cells (49) , raising of antibodies (47) , determination of cytochrome c oxidase activity, analysis of cytochrome spectra (50, 51) , iron content of isolated mitochondria (52) , in vivo labeling of yeast cells with radioactive iron ( 55 FeCl 3 ) and measurement of 55 Fe incorporation into Leu1p and into heme (1, 11, 43) .
RESULTS
Reduced Cytochrome Levels in isc Mutants Are Caused by
Defective Heme Synthesis-To investigate a possible functional connection between the two main iron-metabolizing pathways, we measured the mitochondrial cytochrome content and the heme synthesis rates in a number of isc mutants. We used yeast ISC assembly mutant cells (termed isc mutants) in which the endogenous promoter of the ISC genes was replaced by the inducible GAL1-10 promoter, allowing synthesis of the Isc proteins in the presence and their depletion in the absence of galactose. After depletion, mitochondria were isolated and the specific absence of the respective Isc proteins was confirmed by immunostaining (not shown). First, isolated mitochondria were used for recording cytochrome spectra. A significant reduction of the mitochondrial cytochrome levels was detected in all mutants (Fig. 1A ). In the case of Yah1p and Ssq1p the effect was quite severe. In mitochondria isolated from the mutants Gal-YFH1, Gal-JAC1, and Gal-ISA1, cytochromes were clearly reduced but still detectable.
Next, we measured the activity of cytochrome c oxidase, a mitochondrial enzyme that depends on heme as a cofactor but does not contain Fe/S clusters. Cytochrome c oxidase activity was reduced to a similar extent in all isc mutants tested (Fig.  1B) . These data are consistent with results obtained by Lesuisse et al. that report a severe loss of cytochromes in ⌬yfh1 cells (35) . However, this phenotype was not confined to this ISC assembly component but was generally observed upon affecting any synthesis step of mitochondrial Fe/S proteins. In striking contrast to these results, cytochrome levels and cytochrome c oxidase activity were unaffected upon inactivation of Atm1p or Erv1p, i.e. components of the ISC export machinery (Fig. 1B and data not shown).
What is the reason for the observed reduction of cytochromes and the loss of cytochrome c oxidase activity in isc mutants? To address this question, we compared the de novo heme formation and Fe/S protein synthesis in vivo. Various Isc proteindepleted mutant cells were grown overnight in iron-poor minimal medium followed by radiolabeling with 55 Fe. Newly synthesized, radiolabeled heme was measured by organic extraction of cell lysates (1). Another aliquot of the cell suspension was used to perform an immunoprecipitation with antibodies raised against the cytosolic Fe/S protein Leu1p as a typical marker of cellular Fe/S protein synthesis (11) . Iron incorporation into heme and Leu1p was quantified by liquid scintillation counting. Cells depleted of Yah1p, Nfs1p, or Isu1p displayed a 4 -6-fold lower ability to incorporate 55 Fe into both heme and Fe/S clusters, suggesting a heme synthesis defect in addition to the impairment of Fe/S protein maturation (Fig. 2) . In contrast, cells depleted in non-essential components of the ISC machinery, namely Yfh1p and Isa1p, were only mildly affected in heme synthesis under these conditions. This confirms that Fe/S protein synthesis is the primary function of these ISC components and that the defect in heme synthesis is a secondary consequence (43) . It is important to note in this context that the extent of the in vivo heme synthesis defect depended on the level of depletion of the respective ISC components and on the growth conditions. The different conditions used for 55 Fe labeling under iron-limiting conditions ( Fig. 2 ) and for isolating mitochondria ( Fig. 1) therefore may explain the quantitative differences in heme levels observed in Yfh1p-and Isa1p-depleted cells in vivo and in vitro.
Cells depleted in Atm1p, Erv1p, or glutathione incorporated wild-type amounts of 55 Fe into heme ( Fig. 2 and data not shown). Apparently, mutants defective in cytosolic Fe/S protein maturation, but normal in mitochondrial synthesis of Fe/S clusters (11, 26, 27), were not impaired in heme synthesis, indicating that cytochrome loss and heme synthesis deficiency are restricted to mutants in the mitochondrial ISC assembly machinery. Taken together, these data established that the reduced cytochrome content of isc mutants was, at least to a large extent, the consequence of reduced heme synthesis. Apparently, any decrease of Fe/S cluster synthesis in the mitochondrial matrix is eventually followed by a defect in heme synthesis.
The Last
Step of the Heme Synthesis Pathway Is Defective in isc Mutants-We wondered which step of the complex heme biosynthesis pathway might be affected in the isc mutants. Therefore, we isolated mitochondria from Isc protein-depleted yeast mutants and monitored the ability of the intact organelles to synthesize heme from externally added 55 Fe and deuteroporphyrin (a more soluble protoporphyrin IX homologue; Ref. 1). Mitochondria isolated from all isc mutants tested synthesized 4 -6-fold lower levels of deuteroheme as compared with wild-type or Atm1p-depleted organelles under these experimental conditions, although the amounts of ferrochelatase protein (Hem15p) were similar in all preparations as determined by immunostaining (Fig. 3A) . These data suggest that the heme defects specifically observed in the isc mutants (compare Fig. 1 ) may be caused by an impaired conversion of porphyrin to heme.
To determine whether the diminished heme synthesis was because of defective ferrochelatase activity or impaired transport of substrates across the mitochondrial membranes, we measured the incorporation of 55 Fe into deuteroporphyrin using detergent-solubilized mitochondria, thereby circumventing the transport step. Heme synthesis rates in mitochondrial detergent extracts prepared from isc mutants were not restored upon lysis of the organelles (Fig. 3B) . Efficient iron insertion into deuteroporphyrin was only seen in mitochondrial extracts prepared from wild-type or Atm1p-depleted mitochondria. We also tested by fluorimetric assay the ability of Hem15p in mitochondrial detergent extracts to insert endogenous and added zinc (Zn 2ϩ ) into added protoporphyrin IX (35, 46) . The zinc chelatase activity was strongly inhibited in the isc mutants (4 -10-fold compared with wild-type extracts; not shown). Taken together, the heme synthesis defect observed in the isc mutants is not caused by defective transport of substrates and is not because of an impaired availability of endogenous iron (35) . Rather, our data suggest a general inhibition of Hem15p as a metal chelatase, thus causing the diminished heme syn- A, cytochrome spectra of mitochondria isolated from wild-type (WT) or Gal-YAH1, Gal-SSQ1, Gal-ISA1, Gal-JAC1, and Gal-YFH1 strains (indicated as yah1, ssq1, isa1, jac1, and yfh1, respectively). Cells were cultivated in glucosecontaining media to deplete the Isc proteins and were further grown overnight in lactate medium before mitochondria were isolated. Mitochondria (0.5 mg) were solubilized in detergent-containing buffer and used to record reduced oxidized difference spectra with a Jasco V-550 double beam spectrophotometer. B, cytochrome c oxidase activity of mitochondria isolated from wild-type, Atm1p-depleted Gal-ATM1 (atm1), and the indicated isc mutant cells was determined spectrophotometrically by measuring the disappearance of the 550-nm peak of reduced cytochrome c upon protein-dependent oxidation. Each 1-ml assay contained 5 g of mitochondrial protein and 100 M reduced cytochrome c. Data are given relative to wild-type values. Error bars represent the S.D. (11) . A fraction of the cell suspension was used for organic extraction of radiolabeled heme, which was quantified by liquid scintillation counting. Data are given relative to values obtained for wild-type (WT) cells. Error bars represent the S.E. of the mean. thesis in isc mutants. The specificity for mutations of the ISC assembly and not the export machinery suggests that the inactivation of mitochondrial Fe/S protein maturation creates a situation that does not support the incorporation of iron (or zinc) into porphyrin by Hem15p.
FIG. 2. isc mutants show defects in de novo
heme formation in vivo. Cells were depleted of the indicated Isc proteins or Atm1p and were grown overnight in iron-poor minimal medium containing glucose. After radiolabeling with 55 FeCl 3 , a clarified cell lysate was prepared and used for immunoprecipitation with antibodies against Leu1p (␣-Leu1p). Coprecipitated 55 Fe was quantified by liquid scintillation counting and served as a direct measure for iron incorporated into this cytosolic Fe/S protein
ISC Assembly Components Are Not Directly Involved in
Heme Synthesis-To analyze the reason for the reduced heme synthesis in isc mutants, we considered the possibility that one of the Isc proteins might be directly required for keeping ferrochelatase active or for providing iron for heme synthesis. To this end, we added increasing amounts of protein A-Sepharose beads charged with specific antibodies against Nfs1p, Isu1p, Yah1p, and Yfh1p to deplete mitochondrial detergent extracts of the respective Isc proteins. As a control, we immunodepleted ferrochelatase. Analysis of the supernatants revealed that immunodepletion of Hem15p or the Isc proteins was virtually quantitative (Fig. 4A) . As expected, heme formation in mitochondrial extracts was strongly reduced when ferrochelatase was depleted (Fig. 4B, upper panel) , thereby re-emphasizing that this protein is responsible for the catalytic insertion of iron into heme. Mock treatment with antibodies derived from preimmune serum had no effect. Likewise, immunodepletion of Nfs1p, Isu1p, Yfh1p, or Yah1p did not impair heme synthesis activity in mitochondrial extracts, even if much higher amounts of antibodies were employed than needed for immunodepletion (Fig. 4B, lower panel) . Extracts depleted of Yfh1p incorporated even slightly more 55 Fe into deuteroporphyrin. The reason for this small effect is unknown. Because Yfh1p has been reported to interact with ferrochelatase in plasmon resonance assays (35) (Fig. 4C and data not shown) . Taken together, these results indicate that none of the Isc proteins tested is directly involved in the last step of heme biosynthesis. Furthermore, these data imply that ferrochelatase does not require a specialized iron donor, in particular not Yfh1p.
Immunopurification of Ferrochelatase from isc Mutant Mitochondria Restores Its Activity-Our results demonstrate that the heme synthesis pathway in isc mutant mitochondria was blocked by inhibition or poisoning of ferrochelatase. To analyze this observation in more detail, we used antibodies to immunopurify the enzyme from mitochondria of wild-type cells or various isc mutants. The heme-forming activity of immunopurified ferrochelatase was compared with the activity detectable in the corresponding starting material. Immunopurified, i.e. protein A-Sepharose-coupled ferrochelatase from Gal-NFS1, Gal-YAH1, Gal-JAC1, or Gal-YFH1, cells catalyzed the insertion of iron into deuteroporphyrin as efficiently as ferrochelatase immunopurified from wild-type or Atm1p-depleted Gal-ATM1 cells (Fig. 5A ). The activity of purified ferrochelatase was slightly, but significantly, higher than in wild-type or Atm1p-depleted detergent extracts (see below). Hence, it was possible to recover a fully active ferrochelatase enzyme, even from mitochondrial extracts with impaired heme synthesis. We conclude that ferrochelatase was reversibly inhibited by a compound that is enriched in mitochondria with compromised Fe/S cluster biosynthesis. Apparently, this inhibitor can be removed upon immunopurification of ferrochelatase, resulting in a full restoration of its heme synthesis activity.
To support the observation of the reversible ferrochelatase inhibition, supernatant fractions of the immunodepletion procedure were added back to purified ferrochelatase. The activity of immunopurified ferrochelatase was decreased 4-fold by addition of mitochondrial extracts derived from mutants in the mitochondrial ISC assembly machinery, such as Nfs1p and Yah1p (Fig.  5B) . The extent of inhibition was similar to that found in the starting extracts (see Fig. 5A ). Further, we obtained similar results regardless of whether ferrochelatase was immunopurified from wild-type cells or isc mutants, indicating that the properties of the ferrochelatase protein remained identical in all cell types. Rather weak inhibition was observed by readdition of extracts from wild-type mitochondria or mutant mitochondria depleted in Atm1p. This small effect was consistent with the slightly higher activity of purified ferrochelatase compared with ferrochelatase in mitochondrial detergent extracts (compare Fig. 5A ). In summary, these data unambiguously show that the inhibition of ferrochelatase is fully reversible.
Ferrochelatase Inhibition in isc Mutant Mitochondria Is Caused by a High Molecular Mass
Compound-The reversible character of the ferrochelatase inhibition allowed us to initiate the characterization of the chemical nature of the inhibiting moiety. Because all isc mutants tested accumulate high amounts of iron inside mitochondria, it was conceivable that the accumulated iron could interfere with ferrochelatase function, thereby inhibiting the de novo heme synthesis. However, a comparison of the mitochondrial iron contents in various isc mutants with the defects in mitochondrial and/or cytosolic Fe/S protein biogenesis revealed that the mitochondrial iron accumulation and the heme synthesis defect were not correlated (Table I ). In particular, cells depleted for the ABC transporter Atm1p or cells bearing a temperature-sensitive allele of the sulfhydryl oxidase Erv1p accumulated high amounts of iron in mitochondria but possessed a fully active heme synthesis. In contrast, mitochondria lacking Yfh1p were not capable of synthesizing heme but only showed a comparably moderate iron accumulation. Hence, it seemed unlikely that accumulated iron was responsible for the ferrochelatase inhibition in isc mutants.
To get an idea about the molecular size of the inhibiting compound, we carried out a crude fractionation of mitochondrial detergent extract by passing it through membranes with an exclusion size of 10 or 3 kDa. The fractionated samples were then combined with immunopurified ferrochelatase, and the activity in heme formation was measured. Ferrochelatase was not significantly inhibited when the low molecular mass fractions of the mitochondrial extracts were added (Fig. 6) , excluding that soluble iron or other metal ions caused the inhibition. Instead, a similar inhibition pattern as that observed with the non-fractionated extracts (see Fig. 5B ) was obtained when the high molecular mass fraction was used in the ferrochelatase assay (Fig. 6 ). These data indicate that the reversible ferrochelatase inhibitor behaved as a compound of molecular mass greater than 10 kDa. 50 g of mitochondrial extract without addition of immunobead-coupled antibodies. C, supernatant and pellet (bead) fractions of the immunoprecipitation (IP) using antibodies against Hem15p or preimmune serum (PIS) were analyzed for co-immunoprecipitated Yfh1p by SDS-PAGE and immunostaining. The weak bands in the pellet fraction with PIS are derived from the antiserum and are not because of Hem15p.
FIG. 4. Immunodepletion of Isc proteins does not diminish
heme synthesis activity of mitochondrial extracts. Protein ASepharose beads (PAS) were incubated with the indicated volumes of antisera specific for Hem15p, Isu1p, Nfs1p, Yah1p, and Yfh1p. After washing of the IgG-coupled beads, mitochondrial extracts prepared as described in Fig. 3 were added, and samples were incubated for 30 min at 4°C. Beads and supernatant were separated by centrifugation. A, an aliquot of the supernatant was analyzed by SDS-PAGE and immunostaining for the indicated proteins. The bands marked by asterisks in the top panel represent IgG and a degradation product of IgG; therefore, the full extent of Hem15p depletion is not evident (see panel B) . B, another aliquot of the supernatant (corresponding to 50 g of total mitochondrial protein) was used to measure ferrochelatase activity as described in Fig. 3 . Data are given relative to the activity observed with FIG. 5. Inhibited ferrochelatase in mitochondrial extracts of isc mutants can be reactivated upon purification. A, mitochondrial detergent extracts were prepared from wild-type (WT), Atm1p-depleted Gal-ATM1 (atm1), and the indicated isc mutant cells as described in Fig. 3 . An aliquot was used to determine the ferrochelatase activity (gray bars). Another aliquot was incubated with protein ASepharose coupled to antibodies raised against ferrochelatase (Hem15p). Immunobeads were collected by centrifugation, washed, resuspended in buffer D, and used to measure ferrochelatase activity (white bars). B, ferrochelatase was isolated from wild-type mitochondria by binding to protein A-coupled antibodies as in Fig. 4 . Mitochondria from the indicated cells were lysed in detergent-containing buffer D, and endogenous ferrochelatase was immunodepleted as in Fig. 4 to produce mitochondrial extracts that exhibited only negligible ferrochelatase activity. Purified ferrochelatase and the extracts (equivalent amounts relative to starting material) were combined, and the ferrochelatase activities were measured. -, no extract added; U, M heme formed per min.
DISCUSSION
In this report we present a systematic investigation of a so far poorly understood connection between Fe/S protein and heme biosynthesis in yeast mitochondria. We report that mutants defective in mitochondrial Fe/S protein assembly also display a general reduction of heme and cytochrome levels. To understand the molecular reason for this observation, we measured the ability of various mutants in components of the mitochondrial ISC assembly machinery to synthesize heme in vivo and in vitro. The results indicate that all isc mutants tested were affected in the last step of the heme synthesis pathway, namely the insertion of iron into the porphyrin ring catalyzed by ferrochelatase. Even though the isc mutants contain wild-type amounts of the ferrochelatase protein, the activity of the enzyme was impaired in metal insertion into the porphyrin ring in vivo in isolated mitochondria and in mitochondrial detergent extracts. However, wild-type ferrochelatase activity was restored upon immunopurification of the protein, indicating that the observed heme synthesis defect was caused by reversible inhibition of the enzyme. Initial investigation of the chemical nature of the inhibitor revealed that it fractionated as a high molecular mass compound.
Interestingly, mutants in the ISC export machinery impaired in Fe/S protein biogenesis in the cytosol did not exhibit any heme synthesis defects. This shows that the effect specifically develops during impaired maturation of Fe/S proteins inside mitochondria. We were able to narrow down the reason for the inhibition of heme synthesis observed in isc mutant cells to the last step of the pathway, the ferrochelatase reaction. The enzyme was generally defective in the insertion of metals such as iron and zinc into the porphyrin ring. Even though additional defects in porphyrin synthesis and/or transport of iron or porphyrin precursors across the mitochondrial inner membrane cannot be excluded, we consider such defects unlikely. In fact, normal synthesis of protoporphyrin IX has been found in ⌬yfh1 cells (35) . We therefore assume that the other isc mutant cells also maintain the capability for normal porphyrin synthesis.
The efficiencies of heme synthesis in vivo in isolated mitochondria and in mitochondrial detergent extracts are reduced by a similar extent for most isc mutants. An exception was seen only for mutants displaying a milder growth phenotype (Gal-YFH1 or Gal-ISA1 cells). In vivo under iron-limiting conditions, the mutants showed only a weak effect on heme synthesis despite a significant reduction in Fe/S protein synthesis. This confirms our earlier studies (32, 43) and re-emphasizes the primary function of the Isc proteins in Fe/S protein biogenesis. However, when mitochondria were isolated from these cells, they showed a similar extent of diminished heme synthesis and decreased cytochrome levels as other isc mutants. These data fit well to an earlier study on ⌬yfh1 cells (35) and extend these observations to virtually all isc mutants. However, the diminished heme content of ⌬yfh1 cells cannot be explained by a specific function of frataxin in this process (see also below). Likewise, the proposed unavailability of iron in ⌬yfh1 cells seems unlikely to hold in our conditional isc mutants. Even after addition of iron, ferrochelatase was inactive, rendering it unlikely that the iron precipitation in isc cells may explain the reduced iron incorporation into heme. Together, these data indicate that the observed heme synthesis deficiency appears to be a general, but secondary, consequence of defects in Fe/S protein biosynthesis that develops after shutdown of Fe/S cluster biosynthesis. The actual extent of heme synthesis reduction apparently depends on the phenotypical severity of the various isc mutants and cell cultivation conditions.
One reasonable explanation for the heme synthesis defect in isc mutants could be a dual function of Isc components in both Fe/S protein maturation and heme biosynthesis. Our data render such an interpretation unlikely. First, heme synthesis by ferrochelatase could be restored to wild-type levels upon immunopurification of the enzyme from isc mutant mitochondria. Second, immunodepletion of various Isc proteins from mitochondrial extracts did not impair ferrochelatase activity. Thus, the heme synthesis defects observed in Isc protein-depleted cells in vivo cannot be explained by a second function of the Isc proteins in this process. One suggested candidate for such a dual role was Yfh1p (35) , which functions in iron delivery for Fe/S cluster synthesis (20, 21) . It has been shown that mitochondria isolated from ⌬yfh1 cells lacking Yfh1p are still able to insert endogenous zinc to some extent into protoporphyrin IX (35) . Hence, it was proposed that Yfh1p is required to specifically provide iron to ferrochelatase. We were not able to reproduce these data using our Gal-YFH1 cells. Further, addition of exogenous iron ( 55 Fe) plus ascorbate did not restore the ferrochelatase activity, indicating that the Hem15p defect in Yfh1p-depleted mitochondria cannot be explained by decreased iron availability. In support of these results, by using an in vitro approach with immunodepleted Yfh1p, we have shown that iron incorporation into heme does not depend on the presence of Yfh1p. On the contrary, we observed that heme synthesis became even slightly more efficient upon in vitro depletion of FIG. 6 . Reversible inhibition of ferrochelatase by a high molecular mass compound accumulated in isc mutant mitochondria. Mitochondrial extracts derived from wild-type, Atm1p-depleted Gal-ATM1 (atm1), or the indicated isc mutant cells were immunodepleted for ferrochelatase (see Fig. 4 ). The supernatants were passed through a 10-kDa size exclusion filter (Microcon®; Millipore) to separate a low molecular mass fraction (LM) from a fraction containing most of the proteins (HM). Aliquots were combined with affinity-purified ferrochelatase (equivalent amounts relative to starting material), and deuteroheme synthesis was measured as described in Fig. 5 . (53, 54) . However, a general requirement for Yah1p in heme synthesis has not been reported yet and can be excluded from our in vitro depletion data. Taken together, the ISC components studied here are not directly involved in heme biosynthesis. Ferrochelatases of many organisms such as man and Saccharomyces pombe contain a [2Fe-2S] cluster at the C terminus of the polypeptide chain. This Fe/S cluster is necessary for the activity of the enzyme (5). In addition, it has been suggested that the Fe/S cluster modulates ferrochelatase expression and thus its activity in heme synthesis in response to intracellular iron concentrations (55) . It is therefore worthwhile to consider the possibility that yeast ferrochelatase, lacking an endogenous Fe/S cluster, may depend on an additional, unidentified Fe/S protein. Because such a protein would be matured by the mitochondrial ISC assembly machinery, its existence could explain the heme and cytochrome defects reported here. However, it has long been known that the purified enzyme does not require any other protein for function (4, 46, 56) . Further, we were able to restore the wild-type activities of ferrochelatase upon immunopurification from isc mutants in which synthesis of an Fe/S protein should be precluded. Together, these arguments imply that yeast ferrochelatase does not require an additional Fe/S cofactor to catalyze efficient iron incorporation into heme.
Several results indicate that the inhibition of ferrochelatase in isc mutants is reversible. On the one hand, the inhibitory activity could be removed from ferrochelatase by immunopurification of the enzyme. On the other hand, the activity of purified ferrochelatase was strongly inhibited by adding back extracts prepared from isc mutant mitochondria. This also shows that the inhibitory compound is rather stable. What could be the biochemical nature of the inhibitor? Fractionation of the mitochondrial extracts revealed that the inhibitor of ferrochelatase fractionated as a high molecular mass compound of Ͼ10 kDa. This excludes soluble metabolites and ions. A potential candidate might be the iron accumulated as precipitates in mitochondria of isc mutants (35, 57) . We consider this idea unlikely though because we did not find any correlation between the amounts of accumulated mitochondrial iron and the heme synthesis activity. Provided that the chemical property of the accumulated iron precipitate is similar in all mutant mitochondria, this accumulation cannot be the reason for inhibition. It is reasonable to speculate that the inhibitor might be a protein. However, preliminary experiments showed no protease sensitivity of the inhibitory activity. This finding renders it unlikely that the inhibitor is an Fe/S apoprotein because they are usually highly susceptible to proteolysis. The stability of the inhibitor should facilitate its purification and thereby open insights into the inhibitory mechanism. It will also be interesting to unravel the connection between the inhibitor defined in this work and the suppressor of the heme defects observed in ⌬yfh1 cells (35) . Whether the ferrochelatase inhibition is part of a regulatory network that coordinates the iron distribution between Fe/S cluster synthesis and heme formation will require the identification of the inhibitory agent. Our investigation opens the way to identifying this putative signaling and regulation network that might exist in mitochondria of yeast and possibly higher eukaryotes. Such a posttranslational feedback regulation by enzyme inhibition may be of physiological importance for cellular iron homeostasis because it may give the cell the ability to react quickly to changing environmental conditions and to coordinate the varying needs for heme and Fe/S clusters. For instance, the requirement for heme cofactors should differ substantially when Fe/S cluster synthesis and, in turn, respiration are defective.
It is interesting to discuss whether our yeast findings may be of relevance for mammalian cells. As noted above, human ferrochelatase possesses a C-terminal Fe/S cluster that is essential for function. The cluster has been suggested to contribute one level of regulation of the enzyme by sensing the intracellular iron status (55) . Therefore, defects in mitochondrial Fe/S protein biogenesis should result in diminished heme synthesis. However, with one exception (58) no hematological peculiarities have been documented for patients of Friedreich's ataxia despite lower activities of model Fe/S proteins (see, e.g. Ref. 37) . Probably the reduction of ferrochelatase activity in this disease generally is not strong enough to result in detectable consequences in heme levels. In cases of XLSA/A, which is caused by mutations in the ABC transporter ABC7 (the orthologue of yeast Atm1p), detailed cellular studies are lacking, but a hematological link is evident from elevated erythrocyte protoporphyrin levels and lowered hemoglobin (25) . According to a current model deduced from yeast, the role of ABC7 may be in the biogenesis of cytosolic Fe/S proteins (6); therefore a direct influence on heme synthesis via mitochondrial Fe/S protein defects would not be predicted from our yeast studies. Hence, the severe and broad phenotypes reported for XLSA/A patients, including mitochondrial iron accumulation and loss of mitochondrial DNA, may well be secondary consequences of the mutation in ABC7. We conclude from these considerations that the situation in yeast cannot readily be transferred to mammalian systems. The understanding of the potential functional link between Fe/S protein and heme synthesis in mammals has to come from studies in suitable mouse or cell culture models.
